November 19, 2021
At SAV(Scale Asia Ventures), we are committed to identifying and supporting companies that leverage groundbreaking technology to create transformative solutions. We are proud to announce our investment in Kernal Biologics, a pioneering biotechnology company harnessing the power of machine learning to revolutionize cancer treatment.
Kernal Biologics, founded in 2016, is at the forefront of mRNA research and technology. By employing machine learning algorithms to analyze which proteins cancer ribosomes are more likely to produce and which they are less likely to produce, Kernal Biologics is developing cutting-edge mRNA therapeutics to target cancer cells more effectively and minimize harm to healthy cells.
Kernal Biologics' innovative technology combines the power of machine learning with the emerging field of mRNA therapeutics to create personalized cancer treatments. Key features of their technology include:
Kernal Biologics is a leader in the rapidly growing mRNA space, which has gained significant attention due to its potential to revolutionize cancer treatment and other areas of medicine. By leveraging machine learning to understand cancer ribosomes, Kernal Biologics is well-positioned to develop innovative mRNA therapeutics that could have a significant impact on the way cancer is treated in the future.
The global mRNA therapeutics market is projected to reach $7.4 billion by 2028, driven by the increasing prevalence of chronic diseases and the growing need for personalized medicine. Kernal Biologics' groundbreaking technology and leadership in the mRNA space position the company to capture a significant share of this expanding market.
We believe that Kernal Biologics is uniquely poised to revolutionize cancer treatment through its innovative technology and leadership in the mRNA space. Key reasons for our investment include:
At Scale Asia Ventures, we are excited to partner with Kernal Biologics as they continue to shape the future of cancer treatment and redefine the possibilities of mRNA therapeutics. By investing in this exceptional company, we are confident that we are supporting a transformative force in the biotechnology industry.